Volume 3.30 | Jul 31

Hematopoiesis News 3.30 July 31, 2012
Hematopoiesis News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY
Hematopoietic Stem Cell Development Requires Transient Wnt/ß-Catenin Activity
Researchers suggest that Wnt/ß-catenin activity is transiently required in the aorta-gonad-mesonephros (AGM) to generate long-term hematopoietic stem cells and to produce hematopoietic cells in vitro from AGM endothelial precursors. [J Exp Med] Abstract | Press Release

Visit the Human Immunology Portal for cord blood protocols, tips and other resources
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways that Associate with Disease Progression
Researchers pursued a subnetwork-based analysis of gene expression profiles to discriminate between groups of patients with disparate risks for chronic lymphocytic leukemia progression. [Blood]
Abstract | Press Release

Hydroxyurea and a cGMP-Amplifying Agent Have Immediate Benefits on Acute Vaso-Occlusive Events in Sickle Cell Disease Mice
Scientists showed that inhibition of phosphodiesterase 9, an enzyme highly expressed in hematopoietic cells, amplified the cyclic guanosine monophosphate (cGMP)-elevating effects of hydroxyurea and suggest that this may represent a promising and more tissue-specific adjuvant therapy for this disease. [Blood] Abstract

Immunosuppressive CD14+HLA-DRlow/neg IDO+ Myeloid Cells in Patients following Allogeneic Hematopoietic Stem Cell Transplantation
Scientists identified a T-cell suppressive monocytic population that expands after allo- hematopoietic stem cell transplantation. [Leukemia] Abstract

EVI-1 Modulates Leukemogenic Potential and Apoptosis Sensitivity in Human Acute Lymphoblastic Leukemia
Researchers showed that ecotropic viral integration site-1 (EVI-1) is expressed not only in myeloid but also lymphoid leukemias and contributes to the leukemogenic potential and apoptosis resistance of acute lymphoblastic leukemia cells. [Leukemia] Abstract

Primary Hematopoietic Cells from DBA Patients with Mutations in RPL11 and RPS19 Genes Exhibit Distinct Erythroid Phenotype In Vitro
To develop a mechanistic understanding of Diamond-Blackfan anemia (DBA) pathogenesis, researchers studied CD34+ cells from peripheral blood of DBA patients carrying RPL11 and RPS19 ribosomal gene mutations and determined their ability to undergo erythroid differentiation in vitro. [Cell Death Dis] Full Article

Differential Regulation of CXCL5 by FGF2 in Osteoblastic and Endothelial Niche Cells Supports Hematopoietic Stem Cell Migration
Researchers suggest that the differential regulation of the chemokine CXCL5 between endosteal osteoblasts (OBs) and endothelial cells upon FGF2 treatment is involved in hematopoietic stem cell mobilization from the OB niche or bone marrow to peripheral blood. [Stem Cells Dev] Abstract

The Effects of Zoledronic Acid in the Bone and Vasculature Support of Hematopoietic Stem Cell Niches
The effects of zoledronic acid were investigated on bone marrow cell populations focusing on hematopoietic stem cells and the endosteal and vascular niches in bone. [J Cell Biochem] Abstract

CLINICAL RESEARCH

Nilotinib in Imatinib-Resistant or Imatinib-Intolerant Patients with Chronic Myeloid Leukemia in Chronic Phase: 48- Month Follow-Up Results of a Phase II Study
The 48-month follow-up data for patients with chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance or intolerance on an international phase II study were analyzed. [Leukemia] Abstract

MK-0457, an Aurora Kinase and BCR-ABL Inhibitor, Is Active in Patients with BCR-ABL T315I Leukemia
MK-0457 was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. Researchers found that MK- 0457 has important activity in patients with leukemias expressing the highly resistant T315I BCR-ABL mutation. [Leukemia] Abstract

Brief Intensive Therapy for Older Adults with Newly Diagnosed Burkitt or Atypical Burkitt Lymphoma/Leukemia
Because cyclophosphamide is highly active in Burkitt lymphoma/leukemia (BL) and can be dose-escalated without stem-cell rescue, researchers designed a short, cyclophosphamide-intensive regimen without anthracyclines for patients older than 30 with untreated, non-HIV-associated BL/atypical BL. [Leuk Lymphoma] Abstract

Learn more about the new smartphone app for human blood cell frequencies

INDUSTRY NEWS

NEW: StemSpan™ ACF, the First Plasma Component-Free Hematopoietic Expansion Media
STEMCELL Technologies Inc. announced this week the launch of StemSpan™ ACF, a new animal component-free (ACF) and chemically-defined hematopoietic stem cell expansion medium, which contains no animal and human plasma-derived components. [STEMCELL Technologies Inc.] Press Release

ARIAD Announces Initiation of Randomized Phase III Trial of Ponatinib in Newly Diagnosed Patients with Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. announced the initiation of the randomized Phase III trial of ponatinib in adult patients with newly diagnosed chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc.] Press Release

Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
Bio-Path Holdings, Inc. announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome. [Business Wire] Press Release

American Society of Hematology Launches Multi-Million-Dollar Grant Program to Support Critical Blood Disease Research
The American Society of Hematology announced its commitment of $9 million over a three-year period to provide funding, in the form of bridge grants, for its hematologists whose vital research will not be accomplished due to the severe funding reductions for biomedical research. [American Society of Hematology] Press Release

Stem Cell Agency Commits $150 Million to Develop New Therapies
California’s stem cell agency, the California Institute for Regenerative Medicine approved $150 million in new funding to help move promising stem cell-based therapies from the laboratory research phase to clinical trials in people. [California Institute for Regenerative Medicine] Press Release

Cleveland BioLabs Signs Contract for Approximately $4 Million with Russian Ministry of Industry and Trade for Development of CBLB612
Cleveland BioLabs, Inc. announced that it has signed a contract valued at approximately $4 million, with the Ministry of Industry and Trade of the Russian Federation for development of CBLB612, a drug in development for stimulation of hematopoietic stem cell proliferation and mobilization. [Cleveland BioLabs, Inc.] Press Release


DACOGEN® Receives Positive Regulatory Recommendation in the European Union for Treatment of Acute Myeloid Leukemia
Janssen-Cilag International NV announced that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion recommending approval of DACOGEN® for injection. The CHMP is recommending that DACOGEN be indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia, who are not candidates for standard induction chemotherapy. [Business Wire] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW 8th World Stem Cell Summit
December 3-5, 2012
West Palm Beach, United States

Visit our events page to see a complete list of events in the hematopoietic community.

JOB OPPORTUNITIES

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)


Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)


Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)


Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Position – Hematopoietic Stem Cell Biology and Immunology (University of California, San Francisco)

Postdoctoral Positions – Stem Cells and Immunology (University of Connecticut)

Postdoctoral Position – Stem Cells (Children’s Hospital of Chicago Research Center)



Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us